Haleon plc (LON:HLN) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Haleon plc (LON:HLN) have received a consensus recommendation of “Moderate Buy” from the six brokerages that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is GBX 398.67.

HLN has been the topic of several recent research reports. Berenberg Bank reaffirmed a “buy” rating and set a GBX 512 target price on shares of Haleon in a report on Thursday, April 30th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a GBX 370 target price on shares of Haleon in a report on Thursday, April 30th. Finally, Jefferies Financial Group reduced their target price on shares of Haleon from GBX 450 to GBX 400 and set a “buy” rating on the stock in a report on Tuesday, May 5th.

Haleon Price Performance

HLN stock opened at GBX 334 on Friday. The company has a debt-to-equity ratio of 52.26, a quick ratio of 0.93 and a current ratio of 0.92. Haleon has a 52 week low of GBX 317.80 and a 52 week high of GBX 416.10. The firm’s fifty day moving average is GBX 340.56 and its 200 day moving average is GBX 364.79. The firm has a market cap of £29.55 billion, a P/E ratio of 18.05, a P/E/G ratio of 1.49 and a beta of 0.25.

Insider Transactions at Haleon

In other Haleon news, insider Brian McNamara sold 63,012 shares of the firm’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of GBX 368, for a total value of £231,884.16. 0.01% of the stock is currently owned by company insiders.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.